Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: How many disgruntled shareholders will be urging a chance of management here?

I second that! ALL of that! Well said...er....written.

And it speaks to oneof the larger gripes I have with this BOD is that they think they can make one good move, and get people focus on that, and that it somehow absolves them of a plethora of bad, and possibly technically illegal move(s) considering the close relationship one BOD member has with the receiver of those warrant dividends.

And as for this ENDING the ARS issue, I'll believe it when it is printed in an SEC filing, either 8-K or 10-K, which the company should do forthwith if it actually happens/happened.

Share
New Message
Please login to post a reply